Strategies for Managing Medication-Induced Hyperprolactinemia

Total Page:16

File Type:pdf, Size:1020Kb

Strategies for Managing Medication-Induced Hyperprolactinemia Savvy Psychopharmacology Strategies for managing medication-induced hyperprolactinemia Hilary Navy, PharmD, BCGP, and Kristen Gardner, PharmD, BCPP s. E, age 23, presents to your office functions, including involvement in the syn- for a routine visit for management of thesis and maintenance of breast milk produc- bipolar I disorder and posttraumatic tion, in reproductive behavior, and in luteal M 1,2 stress disorder with comorbid type 2 diabetes function. Hyperprolactinemia—an elevated mellitus. She currently is taking risperidone, prolactin level—is a common endocrinologic 3 mg/d, lamotrigine, 200 mg/d, metformin, disorder of the hypothalamic–pituitary– 2,000 mg/d, medroxyprogesterone, 150 mg axis.3 Children, adolescents, premenopausal Vicki L. Ellingrod, every 3 months, and prazosin, 8 mg/d. Her women, and women in the perinatal period PharmD, FCCP mood has been stabilized for the last 3 years are more vulnerable to medication-induced Department Editor with this medication regimen. hyperprolactinemia.4 If not asymptomatic, Ms. E has a history of self-discontinuing patients with hyperprolactinemia may expe- medication when adverse events occur. She has rience amenorrhea, galactorrhea, hypogo- been hospitalized twice for psychosis and sui- nadism, sexual dysfunction, or infertility.1,4 cide attempts. Past psychotropic medications Chronic hyperprolactinemia may increase that have been discontinued due to adverse the risk for long-term complications, such as effects include ziprasidone (mild abnormal decreased bone mineral density and osteo- lip movement), olanzapine (ineffective and porosis, although available evidence has con- drowsy), valproic acid (tremor and abdomi- flicting findings.1 nal discomfort), lithium (rash), and aripipra- Hyperprolactinemia is diagnosed by a zole (increased fasting blood sugar and labile prolactin concentration above the upper mood). At her appointment today, Ms. E says she is Practice Points concerned because she has been experiencing • In the absence of a tumor, medications are frequently identified as the cause of galactorrhea for the past 4 weeks. Her prolactin hyperprolactinemia. Medication-induced level is 14.4 ng/mL; a normal level for a woman elevated prolactin levels typically range who is not pregnant is <25 ng/mL. However, a from 25 to 100 ng/mL. repeat prolactin level is obtained, and is found • Antipsychotics, antidepressants, to be elevated at 38 ng/mL. hormonal preparations, Savvy Psychopharmacology antihypertensives, and gastrointestinal is produced in partnership Prolactin, a polypeptide hormone that is agents have been associated with with the College hyperprolactinemia. of Psychiatric secreted from the pituitary gland, has many and Neurologic Dr. Navy is Clinical Pharmacy Specialist, PFC Floyd K. Lindstrom • Antipsychotic-induced Pharmacists Outpatient Clinic, VA Eastern Colorado Health Care System, Colorado hyperprolactinemia management cpnp.org Springs, Colorado, and Dr. Gardner is Clinical Pharmacy Specialist, mhc.cpnp.org (journal) Highline Behavioral Health Clinic, Kaiser Permanente Colorado, strategies may include watching and Denver, Colorado. waiting, discontinuing the antipsychotic, Disclosures reducing the antipsychotic dose, switching The authors report no financial relationships with any company antipsychotics, or adding aripiprazole or a Current Psychiatry whose products are mentioned in this article or with manufacturers of dopamine agonist. 42 March 2018 competing products. Savvy Psychopharmacology reference range.3 Various hormones and brexpiprazole, and cariprazine are partial D2 neurotransmitters can impact inhibition or receptor agonists, and cariprazine is the only stimulation of prolactin release.5 For exam- agent that exhibits preferential binding to D3 ple, dopamine tonically inhibits prolactin receptors.12,13 Based on limited data, brexpip- release and synthesis, whereas estrogen razole and cariprazine may have prolactin- stimulates prolactin secretion.1,5 Prolactin also sparing properties given their partial D2 can be elevated under several physiologic receptor agonism.12,13 However, one study and pathologic conditions, such as during found increased prolactin levels in some stressful situations, meals, or sexual activ- patients after treatment with brexpiprazole, ity.1,5 A prolactin level >250 ng/mL is usu- 4 mg/d.14 Similarly, another study found that ally indicative of a prolactinoma; however, cariprazine could increase prolactin levels as some medications, such as strong D2 receptor much as 4.1 ng/mL, depending on the dose.15 antagonists (eg, risperidone, haloperidol), can Except for aripiprazole, brexpiprazole, car- cause significant elevation without evidence iprazine, and clozapine, all other atypical Clinical Point 3 of prolactinoma. In the absence of a tumor, antipsychotics marketed in the United States Typical medications are often identified as the cause have a standard warning in the package of hyperprolactinemia.3 According to the insert regarding prolactin elevations.1,16,17 antipsychotics are Endocrinology Society clinical practice guide- Because antidepressants are less well- more likely to cause line, medication-induced elevated prolactin studied as a cause of medication-induced hyperprolactinemia levels are typically between 25 to 100 ng/mL.3 hyperprolactinemia, drawing definitive con- than atypical clusions regarding incidence rates is limited, antipsychotics Medication-induced but the incidence seems to be fairly low.6,18 hyperprolactinemia A French pharmacovigilance study found Antipsychotics, antidepressants, hormonal that of 182,836 spontaneous adverse drug preparations, antihypertensives, and gastro- events reported between 1985 and 2009, intestinal agents have been associated with there were 159 reports of selective serotonin hyperprolactinemia (Table 1,1,3,5-11 page 44). reuptake inhibitors (SSRIs) inducing hyper- These medication classes increase prolactin prolactinemia.6 Fluoxetine and paroxetine rep- by decreasing dopamine, which facilitates resented about one-half of the cases; however, disinhibition of prolactin synthesis and there were also cases associated with citalo- release, or increasing prolactin stimulating pram, escitalopram, sertraline, fluvoxamine, hormones, such as serotonin or estrogen.5 milnacipran, and venlafaxine. In comparison, Antipsychotics are the most common there were only 11 reports of hyperprolac- medication-related cause of hyperprolac- tinemia associated with tricyclic antidepres- tinemia.3 Typical antipsychotics are more sants or monoamine oxidase inhibitors. likely to cause hyperprolactinemia than Although patients were not always symptom- atypical antipsychotics; the incidence among atic, the most commonly reported symptoms patients taking typical antipsychotics is 40% were galactorrhea (55%), gynecomastia (29%), to 90%.3 Atypical antipsychotics, except amenorrhea (11%), mastodynia (11%), and risperidone and paliperidone, are consid- sexual disorders (4%).6 Another study of 5,920 ered to cause less endocrinologic effects patients treated with fluoxetine found masto- than typical antipsychotics through various dynia in 0.25%, gynecomastia in 0.08%, and mechanisms: serotonergic receptor antago- galactorrhea in 0.07% of patients.18 Symptoms Discuss this article at nism, fast dissociation from D2 receptors, D2 occurred in an extremely low percentage of www.facebook.com/ CurrentPsychiatry receptor partial agonism, and preferential patients, and the study is >20 years old.18 binding of D3 vs D2 receptors.1,5 By having Mirtazapine and bupropion have been transient D2 receptor association, clozapine found to be prolactin-neutral.5 Bupropion and quetiapine are considered to have less also has been reported to decrease prolac- risk of hyperprolactinemia compared with tin levels, potentially via its ability to block Current Psychiatry other atypical antipsychotics.1,5 Aripiprazole, dopamine reuptake.19 Vol. 17, No. 3 43 continued Savvy Psychopharmacology Table 1 Medication-induced hyperprolactinemia Class Medications Mechanism(s) of action Antipsychotics Typical antipsychotics: Chlorpromazine, Antipsychotic-associated D2 receptor haloperidol, thioridazine, thiothixene5 antagonism5 Prolactin-raising atypical antipsychotics: Paliperidone, risperidone1 Antidepressants Serotonin reuptake inhibitors: May release prolactin-regulating Citalopram, escitalopram, fluoxetine, factors, such as vasoactive intestinal fluvoxamine, milnacipran, paroxetine, polypeptide or oxytocin7 6 sertraline, venlafaxine May inhibit the tuberoinfundibular Tricyclic antidepressants: Amitriptyline, dopamine system through the amoxapine, clomipramine, desipramine5 stimulation of GABAergic neurons8 Monoamine oxidase inhibitor: May cause indirect modulation Clinical Point Clorgyline5 of prolactin release by increasing serotonin8 A patient with Hormone Antiandrogens,5 combined oral Estrogen-stimulated lactotroph a prolactin level preparations contraceptives,3 estrogens3 hyperplasia, which stimulates prolactin release9 >100 ng/mL Antihypertensives Methyldopa,5 reserpine,5 Methyldopa inhibits the conversion should be referred tetrabenazine,10 verapamil5 of levodopa to dopamine and can decrease dopamine synthesis by to Endocrinology acting as a false neurotransmitter5,9 to rule out Reserpine can inhibit the storage of hypothalamic catecholamines in prolactinoma secretory granules, which can lead to depletion of dopamine and other sympathetic biogenic amines5 Tetrabenazine is thought to be a reversible depletor of dopamine10 Verapamil blocks
Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
    [Show full text]
  • Commonly Prescribed Psychotropic Medications
    COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Start: IR-100 mg bid X 4d then ↑ to 100 mg tid; SR-150 mg qam X 4d then ↑ to 150 mg Contraindicated in seizure disorder because it decreases seizure threshold; stimulating; not good for treating anxiety disorders; second Bupropion (Wellbutrin) bid; XL-150 mg qam X 4d, then ↑ to 300 mg qam. Range: 300-450 mg/d. line TX for ADHD; abuse potential. ¢ (IR/SR), $ (XL) Citalopram (Celexa) Start: 10-20 mg qday,↑10-20 mg q4-7d to 30-40 mg qday. Range: 20-60 mg/d. Best tolerated of SSRIs; very few and limited CYP 450 interactions; good choice for anxious pt. ¢ Duloxetine (Cymbalta) Start: 30 mg qday X 1 wk, then ↑ to 60 mg qday. Range: 60-120 mg/d. More GI side effects than SSRIs; tx neuropathic pain; need to monitor BP; 2nd line tx for ADHD. $ Escitalopram (Lexapro) Start: 5 mg qday X 4-7d then ↑ to 10 mg qday. Range 10-30 mg/d (3X potent vs. Celexa). Best tolerated of SSRIs, very few and limited CYP 450 interactions. Good choice for anxious pt. $ Fluoxetine (Prozac) Start: 10 mg qam X 4-7d then ↑ to 20 mg qday. Range: 20-60 mg/d. More activating than other SSRIs; long half-life reduces withdrawal (t ½ = 4-6 d). ¢ Mirtazapine (Remeron) Start: 15 mg qhs. X 4-7d then ↑ to 30 mg qhs. Range: 30-60 mg/qhs. Sedating and appetite promoting; Neutropenia risk (1 in 1000) so avoid in immunosupressed patients.
    [Show full text]
  • Prazosin: Preliminary Report and Comparative Studies with Other
    298 BRITISH MEDICAL JOURNAL 1 1 MAY 1974 Prazosin: Preliminary Report and Comparative Studies with Other Antihypertensive Agents Br Med J: first published as 10.1136/bmj.2.5914.298 on 11 May 1974. Downloaded from GORDON S. STOKES, MICHAEL A. WEBER British Medical Journal, 1974, 2, 298-300 bilirubin. One patient had minimal grade 3 hypertensive ocu- lar fundus changes, 10 had grade 1 or 2 changes, and four had normal fundi. Serum crea-tinine concentration was normal in Summary every patient. A diagnosis of uncomplicated essential hypertension was In a group of 14 hypertensive patients a 10-week course made in 12 patients. In two other patients pyelographic of treatment with prazosin 3-7 5 mg/day produced a signifi- evidence of analgesic nephropathy was found. The remaining cant reduction in mean blood pressure without serious side patient had essential hypertension and stable angina pectoris. effects. The fall in diastolic pressure exceeded the response After at least two baseline blood pressure readings, taken mm more to a placebo by 10 Hg or in 9 patients. The average when patients were recumbent and standing, treatment was decrease in diastolic pressure was similar to that produced started with prazosin, 1-mg capsules by mouth, three times or by methyldopa 750 mg/day propranolol 120-160 mg/day daily. Thereafter the patient visited the clinic at intervals of was but the fall in systolic pressure comparatively smaller, one to three weeks. At each visit blood pressure was meas- that the consistent with reported experimental work showing ured to the nearest 5 mm Hg with an Accoson sphygmomo- drug causes vasodilatation.
    [Show full text]
  • Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
    life Review Drug Repurposing for the Management of Depression: Where Do We Stand Currently? Hosna Mohammad Sadeghi 1,†, Ida Adeli 1,† , Taraneh Mousavi 1,2, Marzieh Daniali 1,2, Shekoufeh Nikfar 3,4,5 and Mohammad Abdollahi 1,2,* 1 Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran; [email protected] (H.M.S.); [email protected] (I.A.); [email protected] (T.M.); [email protected] (M.D.) 2 Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran 3 Personalized Medicine Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran 1417614411, Iran; [email protected] 4 Pharmaceutical Sciences Research Center (PSRC) and the Pharmaceutical Management and Economics Research Center (PMERC), Evidence-Based Evaluation of Cost-Effectiveness and Clinical Outcomes Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran 5 Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran * Correspondence: [email protected] † Equally contributed as first authors. Citation: Mohammad Sadeghi, H.; Abstract: A slow rate of new drug discovery and higher costs of new drug development attracted Adeli, I.; Mousavi, T.; Daniali, M.; the attention of scientists and physicians for the repurposing and repositioning of old medications. Nikfar, S.; Abdollahi, M. Drug Experimental studies and off-label use of drugs have helped drive data for further studies of ap- Repurposing for the Management of proving these medications.
    [Show full text]
  • The American Journal Of
    The American Journal of Psychiatry Residents’ Journal July 2015 Volume 10 Issue 7 Inside IN THIS ISSUE 2 New Formats and New Opportunities: The Time to Get Involved is “Now”! Rajiv Radhakrishnan, M.B.B.S., M.D. 3 Prevention of Posttraumatic Stress Disorder: Predicting Response to Trauma Jennifer H. Harris, M.D. 7 Weight Gain in Patients With Schizophrenia: A Recipe For Timely Intervention Ammar El Sara, M.B.Ch.B. 10 Hyperprolactinemia and Antipsychotics: Update for the Training Psychiatrist Stephanie Pope, M.D. 13 A Clinical Case Conference on Spiritual Growth and Healing Elizabeth S. Stevens, D.O. This issue of the Residents’ Journal features a variety of topics. Jennifer H. Har- ris, M.D., discusses prevention of posttraumatic stress disorder, with an overview 15 Priapism: A Rare but Serious of various responses to trauma. Ammar El Sara, M.B.Ch.B., presents a review of Side Effect of Trazodone clinically applicable evidence-based interventions targeting obesity in schizophre- Kamalika Roy, M.D. nia patients. Stephanie Pope, M.D., examines antipsychotic-induced hyperprolac- 17 Classifying Psychopathology: tinemia, including variables affecting prolactin and clinical implications. Elizabeth Mental Kinds and Natural Kinds S. Stevens, D.O., discusses several psychological, social, and spiritual developmen- Reviewed by Aaron J. Hauptman, tal frameworks in a clinical case conference. Kamalika Roy, M.D., presents a case M.D. of priapism as a side effect of trazodone in a middle-aged patient. Lastly, Aaron J. Hauptman, M.D., offers his review of the book Classifying Psychopathology: Mental 18 Residents’ Resources Kinds and Natural Kinds. Editor-in-Chief Associate Editors Editors Emeriti Rajiv Radhakrishnan, M.B.B.S., M.D.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Efficacy of Antimanic Treatments: Meta-Analysis of Randomized, Controlled Trials
    Neuropsychopharmacology (2011) 36, 375–389 & 2011 American College of Neuropsychopharmacology. All rights reserved 0893-133X/11 $32.00 www.neuropsychopharmacology.org Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials ,1,2 2,3 4 2 Ays¸egu¨l Yildiz* , Eduard Vieta , Stefan Leucht and Ross J Baldessarini 1 2 Department of Psychiatry, Dokuz Eylu¨l University, Izmir, Turkey; Department of Psychiatry, Harvard Medical School and International Consortium for Bipolar Disorder Research and Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, 3 Massachusetts; Bipolar Disorders Program, Institute of Clinical Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, 4 Barcelona, Spain; Department of Psychiatry and Psychotherapy, Klinik fu¨r Psychiatrie und Psychotherapie der TU-Mu¨nchen, Klinikum rechts der Isar, Technische Universita¨t Mu¨nchen, Mu¨nchen, Germany We conducted meta-analyses of findings from randomized, placebo-controlled, short-term trials for acute mania in manic or mixed states of DSM (III–IV) bipolar I disorder in 56 drug–placebo comparisons of 17 agents from 38 studies involving 10 800 patients. Of drugs tested, 13 (76%) were more effective than placebo: aripiprazole, asenapine, carbamazepine, cariprazine, haloperidol, lithium, olanzapine, paliperdone, quetiapine, risperidone, tamoxifen, valproate, and ziprasidone. Their pooled effect size for mania improvement (Hedges’ g in 48 trials) was 0.42 (confidence interval (CI): 0.36–0.48); pooled responder risk ratio (46 trials) was 1.52 (CI: 1.42–1.62); responder rate difference (RD) was 17% (drug: 48%, placebo: 31%), yielding an estimated number-needed-to-treat of 6 (all po0.0001). In several direct comparisons, responses to various antipsychotics were somewhat greater or more rapid than lithium, valproate, or carbamazepine; lithium did not differ from valproate, nor did second generation antipsychotics differ from haloperidol.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Medication Adherence, Health Care Utilization, and Costs in Patients with Major Depressive Disorder Initiating Adjunctive Atypical * Antipsychotic Treatment
    Clinical Therapeutics/Volume 41, Number 2, 2019 Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical * Antipsychotic Treatment Michael S. Broder, MD, MSHS1; Mallik Greene, BPharm, PhD, DBA2; Tingjian Yan, PhD1; Eunice Chang, PhD1; Ann Hartry, PhD3; and Irina Yermilov, MD, MPH, MS1 1Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA; 2Otsuka Phar- maceutical Development & Commercialization, Inc, Princeton, NJ, USA; and 3Lundbeck, Deerfield, IL, USA ABSTRACT (HR ¼ 1.14; 95% CI, 1.00e1.29; P ¼ 0.054). The adjusted rate of all-cause hospitalization or emergency Purpose: The purpose of this study was to compare department visit in the postindex period was lowest for medication adherence, health care utilization, and cost brexpiprazole at 27.4% (95% CI, 24.0%e31.0%), among patients receiving adjunctive treatment for compared with 31.1% (95% CI, 27.3%e35.2%) for major depressive disorder (MDD) with brexpiprazole, lurasidone and 35.3% (95% CI, 33.5%e37.1%) for quetiapine, or lurasidone. quetiapine (P< 0.001 for all comparisons). Quetiapine Methods: UsingTruvenHealthMarketScan® users had increased all-cause costs compared with Commercial, Medicaid, and Medicare Supplemental brexpiprazole users (estimate ¼ $2309; 95% CI, Databases, we identified adults with MDD initiating $31e$4587; P ¼ 0.047); all-cause medical costs did not adjunctive treatment with brexpiprazole, quetiapine, or differ between lurasidone and brexpiprazole lurasidone (index atypical antipsychotic [AAP]). We (estimate ¼ $913; 95% CI, $−2033 e$3859; P ¼ 0.543). compared medication adherence and persistence Adjusted psychiatric hospital care, psychiatric costs, and measured by proportion of days covered (PDC) and PDC did not differ significantly among the groups.
    [Show full text]
  • Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia
    brain sciences Review Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia Samskruthi Madireddy 1,* and Sahithi Madireddy 2 1 Independent Researcher, 1353 Tanaka Drive, San Jose, CA 95131, USA 2 Massachusetts Institute of Technology, 77 Massachusetts Ave, Cambridge, MA 02139, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-408-9214162 Received: 4 September 2020; Accepted: 15 October 2020; Published: 16 October 2020 Abstract: The biochemical integrity of the brain is paramount to the function of the central nervous system, and oxidative stress is a key contributor to cerebral biochemical impairment. Oxidative stress, which occurs when an imbalance arises between the production of reactive oxygen species (ROS) and the efficacy of the antioxidant defense mechanism, is believed to play a role in the pathophysiology of various brain disorders. One such disorder, schizophrenia, not only causes lifelong disability but also induces severe emotional distress; however, because of its onset in early adolescence or adulthood and its progressive development, consuming natural antioxidant products may help regulate the pathogenesis of schizophrenia. Therefore, elucidating the functions of ROS and dietary antioxidants in the pathogenesis of schizophrenia could help formulate improved therapeutic strategies for its prevention and treatment. This review focuses specifically on the roles of ROS and oxidative damage in the pathophysiology of schizophrenia, as well as the effects of nutrition, antipsychotic use, cognitive therapies, and quality of life on patients with schizophrenia. By improving our understanding of the effects of various nutrients on schizophrenia, it may become possible to develop nutritional strategies and supplements to treat the disorder, alleviate its symptoms, and facilitate long-term recovery.
    [Show full text]
  • Cariprazine Exhibits Anxiolytic and Dopamine D Receptor-Dependent
    International Journal of Neuropsychopharmacology (2017) 20(10): 788–796 doi:10.1093/ijnp/pyx038 Advance Access Publication: May 22, 2017 Regular Research Article regular research article Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model Vanja Duric, Mounira Banasr, Tina Franklin, Ashley Lepack, Nika Adham, Béla Kiss, István Gyertyán, Ronald S. Duman Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut (Dr Duric, Dr Banasr, Dr Franklin, Ms Lepack, and Dr Duman); Department of Physiology and Pharmacology, Des Moines University, Des Moines, Iowa (Dr Duric); Campell Family Mental Health Research Institute of CAMH, Toronto, Ontario, Canada (Dr Banasr); Department of Pharmacology, Allergan, Jersey City, New Jersey (Dr Adham); Pharmacological and Safety Research, Gedeon Richter Plc, Budapest, Hungary (Dr Kiss); MTA-SE NAP B Cognitive Translational Behavioral Pharmacology Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary (Dr Gyertyán); Institute of Cognitive Neuroscience and Psychology, Hungarian Academy of Sciences, Budapest, Hungary (Dr Gyertyán). Correspondence: Ronald S. Duman, PhD, Professor of Psychiatry and Pharmacology, Director, Abraham Ribicoff Research Facilities, Laboratory of Molecular Psychiatry, Yale University School of Medicine, 34 Park Street, Room 308, New Haven, CT 06508 ([email protected]). Abstract Background: Cariprazine, a D3-preferring dopamine D2/D3 receptor partial agonist, is a new antipsychotic drug recently approved in the United States for the treatment of schizophrenia and bipolar mania. We recently demonstrated that cariprazine also has significant antianhedonic-like effects in rats subjected to chronic stress; however, the exact mechanism of action for cariprazine’s antidepressant-like properties is not known.
    [Show full text]